OncoZenge AB (publ) (ONCOZ.ST)
SEK 4.28
(-4.36%)
SEK 4.28
(-4.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -15.9 Million SEK | 65.91% |
| 2022 | -46.64 Million SEK | -1100.36% |
| 2021 | -3.88 Million SEK | -511.01% |
| 2020 | -636 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -2.37 Million SEK | 25.17% |
| 2024 Q2 | -2.05 Million SEK | 13.45% |
| 2023 Q1 | -4.05 Million SEK | 11.02% |
| 2023 FY | -15.9 Million SEK | 65.91% |
| 2023 Q3 | -4.18 Million SEK | 6.79% |
| 2023 Q2 | -4.49 Million SEK | -10.83% |
| 2023 Q4 | -3.17 Million SEK | 24.29% |
| 2022 Q4 | -4.55 Million SEK | -42.03% |
| 2022 FY | -46.64 Million SEK | -1100.36% |
| 2022 Q3 | -3.2 Million SEK | -13.64% |
| 2022 Q2 | -2.82 Million SEK | 92.17% |
| 2022 Q1 | -36.06 Million SEK | -3205.41% |
| 2021 Q3 | -784 Thousand SEK | 21.6% |
| 2021 Q2 | -1 Million SEK | 1.09% |
| 2021 Q1 | -1.01 Million SEK | 0.0% |
| 2021 Q4 | -1.09 Million SEK | -39.16% |
| 2021 FY | -3.88 Million SEK | -511.01% |
| 2020 FY | -636 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 65.279% |
| Biovica International AB (publ) | -124.82 Million SEK | 87.26% |
| Cantargia AB (publ) | -280.02 Million SEK | 94.321% |
| CombiGene AB (publ) | -35.66 Million SEK | 55.413% |
| Cyxone AB (publ) | -22.98 Million SEK | 30.828% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -36.171% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 3.025% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 82.602% |
| Fluicell AB (publ) | -26.55 Million SEK | 40.114% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 87.079% |
| Mendus AB (publ) | -101.61 Million SEK | 84.351% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 57.104% |
| I-Tech AB | 20.2 Million SEK | 178.711% |
| Intervacc AB (publ) | -102.85 Million SEK | 84.539% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -31.118% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 230.676% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 11.147% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3530.594% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.903% |
| Lipum AB (publ) | -37.17 Million SEK | 57.227% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 93.603% |
| Ziccum AB (publ) | -21.41 Million SEK | 25.733% |
| BioArctic AB (publ) | 229.24 Million SEK | 106.937% |
| Genovis AB (publ.) | 61.5 Million SEK | 125.857% |
| Camurus AB (publ) | 431.44 Million SEK | 103.686% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 91.058% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 72.014% |
| Aptahem AB (publ) | -11.11 Million SEK | -43.095% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.886% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 91.149% |
| Kancera AB (publ) | -64.88 Million SEK | 75.494% |
| Saniona AB (publ) | -95.81 Million SEK | 83.403% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 62.338% |
| AcouSort AB (publ) | -17.08 Million SEK | 6.946% |
| Xintela AB (publ) | -54.08 Million SEK | 70.597% |
| Abliva AB (publ) | -95.5 Million SEK | 83.35% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 395.247% |
| Amniotics AB (publ) | -30.87 Million SEK | 48.487% |
| 2cureX AB (publ) | -32.51 Million SEK | 51.098% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -23.963% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.589% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.088% |
| Biosergen AB | -27.03 Million SEK | 41.184% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 3.758% |
| Corline Biomedical AB | -1.8 Million SEK | -779.049% |
| NextCell Pharma AB | -41.95 Million SEK | 62.102% |
| Nanologica AB (publ) | -75.15 Million SEK | 78.842% |
| LIDDS AB (publ) | -40.2 Million SEK | 60.449% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 95.136% |
| BioInvent International AB (publ) | -330.3 Million SEK | 95.186% |
| SynAct Pharma AB | -215.81 Million SEK | 92.631% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 63.903% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 33.008% |
| Alzinova AB (publ) | -16.48 Million SEK | 3.507% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 85.449% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 93.617% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -60.141% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 85.968% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 24.603% |
| Simris Alg AB (publ) | -37.3 Million SEK | 57.373% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 89.528% |